Bioactive lipid mediators in polycystic kidney disease

Journal of Lipid Research

Volumn 55, Issue 6, 2014, Pages 1139-1149

  Klawitter, Jelena ^a,b   Klawitter, Jost ^a   McFann, Kim ^b   Pennington, Alexander T ^a   Abebe, Kaleab Z ^c   Brosnahan, Godela ^b   Cadnapaphornchai, Melissa A ^b   Chonchol, Michel ^b   Gitomer, Berenice ^b   Christians, Uwe ^a   Schrier, Robert W ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Arachidonic acid; Autosomal dominant polycystic kidney disease; Bioactive lipid biomarkers; Liquid chromatography mass spectrometry

Indexed keywords

11 HETE; 12 HEPE; 12 HYDROXYICOSATETRAENOIC ACID; 13 HODE; 15 HEPE; 15 HYDROXYICOSATETRAENOIC ACID; 17S HDHA; 18 HEPE; 20 HYDROXYICOSATETRAENOIC ACID; 5 HEPE; 5 HYDROXYICOSATETRAENOIC ACID; 8 HEPE; 8 HETE; 9 HEPE; 9 HETE; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; BIOACTIVE LIPID MEDIATOR; BIOLOGICAL MARKER; DIMORPHECOLIC ACID; FATTY ACID; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; 12-15-LIPOXYGENASE; CONJUGATED LINOLEIC ACID;

ADULT; ARTICLE; BODY SURFACE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ESTIMATED GLOMERULAR FILTRATION RATE; FATTY ACID METABOLISM; FEMALE; HUMAN; INFLAMMATION; KIDNEY POLYCYSTIC DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; RENAL SYSTEM PARAMETERS; TOTAL KIDNEY VOLUME; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; FEMALE; HUMANS; LINOLEIC ACIDS, CONJUGATED; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 84901651371     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P042176     Document Type: Article

References (77)

1. Perrone, R. D., R. Ruthazer, and N. C. Terrin. 2001. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 38: 777-784.
2. Filiopoul os, V., and D. Vlassopoulos. 2009. Infl ammatory syndrome in chronic kidney disease: pathogenesis and infl uence on outcomes. Infl amm. Allergy Drug Targets. 8: 369-382.
3. Small, D. M., J. S. Coombes, N. Bennett, D. W. Johnson, and G. C. Gobe. 2012. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton). 17: 311-321.
4. Perrone, R. D., K. Z. Abebe, R. W. Sc hrier, A. B. Chapman, V. E. Torres, J. Bost, D. Kaya, D. C. Miskulin, T. I. Steinman, W. Braun, et al. 2011. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney diseas e. Clin. J. Am. Soc. Nephrol. 6: 2508-2515.
5. Bardají , A., A. Martinez-Vea, A. Valero, C. Gutierrez, C. Garcia, C. Ridao, J. A. Oliver, and C. Richart. 2001. Cardiac involvement in aut osomal-dominant polycystic kidney disease: a hypertensive heart disease. Clin. Nephrol. 56: 211-220.
6. Alam, A., and R. D. Perrone. 2013. Left ventricular hypertrophy in ADPKD: changing demographics. Curr. Hypertens. Rev. 9: 27-31.
7. Mitchell, G. F., N. Wang, J. N. Palmisano, M. G. Larson, N. M. Hamburg, J. A. Vita, D. Levy, E. J. Benjamin, and R. S. Vasan. 2010. Hemodynamic correl ates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study. Circulation. 122: 1379-1386.
8. Tomiyama, H., H. Tanaka, H. Hashimoto, C. Matsumoto, M. Odaira, J. Yamada, M. Yoshida, K. Shiina, M. Nagata, and A. Yamashina. 2010. Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease. Atherosclerosis. 212: 345-350.
9. Tonelli, M., F. Sacks, M. Pfeffer, G. S. Jhangri, and G. Curhan. 2005. Biomarkers of infl ammation and progression of chronic kidney disease. Kidney Int. 68: 237-245.
10. Borresen, M. L., D. Wang, and S. Strandgaard. 2007. Pulse wave refl ection is amplifi ed in normotensive patients with autosomaldominant polycystic kidney disease and normal renal function. Am. J. Nephrol. 27: 240-246.
11. Lieb, W., M. G. Larson, E. J. Benjamin, X. Yin, G. H. Tofl er, J. Selhub, P. F. Jacques, T. J. Wang, J. A. Vita, D. Levy, et al. 2009. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Hear t Study. Circulation. 119: 37-43.
12. Schnabel, R., M. G. Larson, J. Dupuis, K. L. Lunetta, I. Lipinska, J. B. Meigs, X. Yin, J. Rong, J. A. Vita, C. Newton-Cheh, et al. 2008. Relations of infl ammatory biomarkers and common genetic variants with arterial stiffness and wave refl ection. Hypertension. 51: 1651-1657.
13. Merta, M., V. Tesar, T. Zima, M. Jirsa, R. Rysava, and J. Zabka. 1997. Cytokine profi le in autosomal dominant polycystic kidney disease. Biochem. Mol. Biol. Int. 41: 619-624.
14. Park, E. Y., M. J. Seo, and J. H. Park. 2010. Effects of spec ifi c genes activating RAGE on polycystic kidney disease. Am. J. Nephrol. 32: 169-178.
15. Heffernan, K. S., E. A. Patvardhan, M. Hession, J. Ruan, R. H. Karas, and J. T. Kuvin. 2010. Elevated augmentation index derived from peripheral arterial tonometry is associated with abnormal ventricular-vascular coupling. Clin. Physiol. Funct. Imaging. 30: 313-317.
16. Heffernan, K. S., J. T. Kuvin, M. J. Sarnak, R. D. Perrone, D. C. Miskulin, D. Rudym, P. Chandra, R. H. Karas, and V. Menon. 2011. Peripheral augmentation index and vascular infl ammation in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 26: 2515-2521.
17. Menon V.,D. Rudym,P. Chandra,D. Miskulin,R. Perrone,M. Sarnak.,2011. Infl ammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin. J. Am. Soc. Nephrol.,6,7-13.
18. van Dijk, M. A., A. M. Kamper, S. van Veen, J. H. Souverijn, and G. J. Blauw. 2001. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 16: 2152-2157.
19. Namli, S., H. Ofl az, F. Turgut, S. Alisir, F. Tufan, A. Ucar, F. Mercanoglu, and T. Ecder. 2007. Improvement of endothelial dysf unction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren. Fail. 29: 55-59.
20. Harris, M. B., M. A. Blackstone, S. G. Sood, C. Li, J. M. Goolsby, V. J. Venema, B. E. Kemp, and R. C. Venema. 2004. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am. J. Physiol. Heart Circ. Physiol. 287: H560-H566.
21. Hernández- Perera, O., D. Pérez-Sala, J. Navarro-Antolín, R. Sánchez-Pascuala, G. Hernández, C. Díaz, and S. Lamas. 1998. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the express ion of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101: 2711-2719.
22. Mulhaupt, F., C. M. Matter, B. R. Kwak, G. Pelli, N. R. Veillard, F. Burger, P. Graber, T. F. Luscher, and F. Mach. 2003. Statins (HMGCoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res. 59: 755-766.
23. Rezaie-Majd, A., G. W. Prager, R. A. Bucek, G. H. Schernthaner, T. Maca, H. G. Kress, P. Valent, B. R. Binder, E. Minar, and M. Baghestanian. 2003. Simvastatin reduces the expression of adhes ion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 23: 397-403.
24. Dailey, L. A., and P. Imming. 1999. 12-Lipoxygenase: classifi cation, possible therapeutic benefi ts from inhibition, and inhibitors. Curr. Med. Chem. 6: 389-398.
25. Wu, X. C., N. T. Richards, J. Michael, and E. Johns. 1994. Relative roles of nitric oxide and cyclo-oxygenase and l ipoxygenase products of arachidonic acid in the contractile responses of rat renal arcuate arteries. Br. J. Pharmacol. 112: 369-376.
26. Zhao, L., and C. D. Funk. 2004. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc. Med. 14: 191-195.
27. Kim, Y. S., Z. G. Xu, M. A. Reddy, S. L. Li, L. Lanting, K. Sharma, S. G. Adler, and R. Natarajan. 2005. Novel interactions between TGF-{beta} 1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J. Am. Soc. Nephrol. 16: 352-362.
28. Node, K., Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley, D. C. Zeldin, and J. K. Liao. 1999. Anti-infl ammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285: 1276-1279.
29. Serhan, C. N., and J. Savill. 2005. Resolution of infl ammation: the beginning programs the end. Nat. Immunol. 6: 1191-1197.
30. Imig, J. D. 2005. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289: F496-F503.
31. Imig, J. D. 2006. Eicosanoids and renal vascular function in diseases. Clin. Sci. (Lond.). 111: 21-34.
32. Sarkis, A., B. Lopez, and R. J. Roman. 2004. Role of 20- hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr. Opin. Nephrol. Hypertens. 13: 205-214.
33. Shureiqi, I., and S . M. Lippman. 2001. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 61: 6307-6312.
34. Levey, A. S., J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth. 1999. A more accurate method to estimate glomerular fi ltration rate from serum creatinine: a new prediction equation. Modifi cation of Diet in Renal Disease Study Group. Ann. Intern. Med. 130: 461-470.
35. Masoodi, M., A. A. Mir, N. A. Petasis, C. N. Serhan, and A. Nicolaou. 2008. Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/ele ctrospray ionisation tandem mass spectrometry. Rapid Commun. Mass Spectrom. 22: 75-83.
36. Chapman, A. B., V. E. Torres, R. D. Perrone, T. I. Steinman, K. T. Bae, J. P. Miller, D. C. Miskulin, F. Rahbari Oskoui, A. Masoumi, M. C. Hogan, et al. 2010. The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 5: 102-109.
37. Torres, V. E., A. B. Chapman, R. D. Perrone, K. T. Bae, K. Z. Abebe, J. E. Bost, D. C. Miskulin, T. I. Steinman, W. E. Braun, F. T. Winklhofer, et al. 2012. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney In t. 81: 577-585.
38. Funk C.D,2001,Prostaglandins and leukotrienes: advances in eicosanoid biology, Science.,294, 1871-1875.
39. Massey, K. A., and A. Nicolaou. 2011. Lipidomics of polyunsaturatedfatty- acid-derived oxygenated metabolites. Biochem. Soc. Trans. 39: 1240-1246.
40. Medhora, M., A. Dhanasekaran, S. K. Gruenloh, L. K. Dunn, M. Gabrilovich, J. R. Falck, D. R. Harder, E. R. Jacobs, and P. F. Pratt. 2007. Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat. 82: 19-29.
41. Baer, A. N., P. B. Costello, and F. A. Green. 1991. Stereospecifi city of the hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids produced by cultured bovine endothelial cells. Biochim. Biophys. Acta. 1085: 45-52.
42. Kü hn, H. 1996. Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero) XY-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13- hydro(pero)XY-9Z,11E- octadecadienoic acid. Prog. Lipid Res. 35: 203-226.
43. Fang, X., T. L. Kaduce, and A. A. Spector. 1999. 13-(S)- hydroxyoctadecadienoic acid (13-HODE) incorporation and conversion to novel products by endothelial cells. J. Lipid Res. 40: 699-707.
44. Kuhn, H. 2005. Biologic relevanc e of lipoxygenase isoforms in atherogenesis. Expert Rev. Cardiovasc. Ther. 3: 1099-1110.
45. Dobrian, A. D., D. C. Lieb, B. K. Cole, D. A. Taylor-Fishwick, S. K. Chakrabarti, and J. L. Nadler. 2011. Functional and pathological roles of the 12-and 15-lipoxygenases. Prog. Lipid Res. 50: 115-131.
46. Camara, N. O., J. O. Martins, R. G. Landgraf, and S. Jancar. 2009. Emerging roles for eicosanoids in renal diseases. Curr. Opin. Nephrol. Hypertens. 18: 21-27.
47. Hao, C. M., and M. D. Breyer. 2007. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int. 71: 1105-1115.
48. Roman, R. J. 2002. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82: 131-185.
49. Hoagland, K. M., K. G. Maier, C. Moreno, M. Yu, and R. J. Roman. 2001. Cytochrome P450 metabolites of arachidonic acid: novel regulators of renal function. Nephrol. Dial. Transplant. 16: 2283-2285.
50. Serhan, C. N., C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, and K. Gronert. 2000. Novel functional sets of lipid-derived med iators with antiinfl ammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinfl ammatory drugs and transcellular processing. J. Exp. Med. 192: 1197-1204.
51. Theken, K. N., R. N. Sc huck, M. L. Edin, B. Tran, K. Ellis, A. Bass, F. B. Lih, K. B. Tomer, S. M. Poloyac, M. C. Wu, et al. 2012. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular dis ease. Atherosclerosis. 222: 530-536.
52. Fleming, I. 2001. Cytochrome p450 and vascular homeostasis. Circ. Res. 89: 753-762.
53. Topol, E. J., J. Smith, E. F. Plow, and Q. K. Wang. 2006. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum. Mol. Genet. 15 ( Spec No 2 ): R117-R123.
54. Listì , F., M. Caruso, E. Incalcaterra, E. Hoffmann, G. Caimi, C. R. Balistreri, S. Vasto, V. Scafi di, C. Caruso, and G. Candore. 2008. Proinfl ammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr. Pharm. Des. 14: 2678-2685.
55. Hughes, H., D. L. Gentry, G. M. McGuire, and A. A. Taylor. 1991. Gas chromatographic-mass spectrometric analysis of lipoxygenase products in post-ischemic rabbit myocardium. Prostaglandins Le ukot. Essent. Fatty Acids. 42: 225-231.
56. Barrett, B. J., R. Foley, J. Morgan, D. Hefferton, and P. Parfrey. 1994. Differences in hormonal and renal vascular responses between normotensive patie nts with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int. 46: 1118-1123.
57. Chapman, A. B., A. Johnson, P. A. Gabow, and R. W. Schrier. 1990. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 323: 1091-1096.
58. Wang, D., S. Strandgaard, M. L. Borresen, Z. Luo, S. G. Connors, Q. Yan, and C. S. Wilcox. 2008. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 51: 184-191.
59. Xu, Z. G., H. Yuan, L. Lanting, S. L. Li, M. Wang, N. Shanmugam, M. Kato, S. G. Adler, M. A. Reddy, and R. Natarajan. 2008. Products of 12/15-lipoxygenase upregulate the angiotensin II receptor. J. Am. Soc. Ne phrol. 19: 559-569.
60. Reddy, M. A., S. G. Adler, Y. S. Kim, L. Lanting, J. Rossi, S. W. Kang, J. L. Nadler, A. Shahed, and R. Natarajan. 2002. Interaction of MAPK and 12-lipoxyge nase pathways in growth and matrix protein expression in mesangial cells. Am. J. Physiol. Renal Physiol. 283: F985-F994.
61. Brunner, H. R. 2001. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am. J. Cardiol. 87: 3C-9C.
62. Laursen, J. B., S. Rajagopalan, Z. Galis, M. Tarpey, B. A. Freeman, and D. G. Harrison. 1997. Role of superoxide i n angiotensin IIinduced but not catecholamine-induced hypertension. Circulation. 95: 588-593.
63. Watanabe, T., T. A. Barker, and B. C. Berk. 2005. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 45: 163-169.
64. Kim, G. Y., J. W. Lee, S. H. Cho, J. M. Seo, and J. H. Kim. 2009. Role of the low-affi nity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 29: 915-920.
65. Viita, H., J. Markkanen, E. Eriksson, M. Nurminen, K. Kinnunen, M. Babu, T. Heikura, S. Turpeinen, S. Laidinen, T. Takalo, et al. 2 008. 15-lipoxygenase-1 prevents vascular endothelial growth factor A-and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 e xpression. Circ. Res. 102: 177-184.
66. Shappell, S. B., S. J. Olson, S. E. Hannah, S. Manning, R. L. Roberts, N. Masumori, M. Jisaka, W. E. Boeglin, V. Vader, D. S. Dave, et al. 2003. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res. 63: 2256-2267.
67. Bello-Reuss, E., K. Holubec, and S. Rajaraman. 2001. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int. 60: 37-45.
68. Reed, B. Y., A. Masoumi, E. Elhassan, K. McFann, M. A. Cadnapaphornchai, D. M. Maahs, J. K. Snell-Bergeon, and R. W. Schrier. 2011. Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int. 79: 128-134.
69. Grimm, H., K. Mayer, P. Mayser, and E. Eigenbrodt. 2002. Regulatory potential of n-3 fatty acids in immunological and infl ammatory processes. Br. J. Nutr. 87 ( Suppl 1 ): S59-S67.
70. Serhan, C. N., N. Chia ng, and T. E. Van Dyke. 2008. Resolving infl ammation: dual anti-infl ammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361.
71. Poulsen, R. C., K. H. Gotlinger, C. N. Serhan, and M. C. Kruger. 2008. Identifi cation of infl ammatory and proresolving lipid mediators in bone marrow and their lipidomic profi les with ovariectomy and omega-3 intake. Am. J. Hematol. 83: 437-445.
72. Alonso -Galicia, M., K. G. Maier, A. S. Greene, A. W. Cowley, Jr., and R. J. Roman. 2002. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R60-R68.
73. Cheng, J., C. C. Wu, K. H. Gotlinger, F. Zhang, J. R. Falck, D. Narsimhaswamy, and M. L. Schwartzman. 2010. 20-hydroxy-5,8,11, 14-eicosatetraenoic acid mediates endothelia l dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J. Pharmacol. Exp. Ther. 332: 57-65.
74. Park, F., W. E. Sweeney, Jr., G. Jia, T. Akbulut, B. Mueller, J. R. Falck, S. Birudaraju, R. J. Roman, and E. D. Avner. 2009. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD. Am. J. Physiol. Renal Physiol. 296: F575-F582.
75. Escalante, B. A., J. C. McGiff, and A. O. Oyekan. 2002. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am. J. Physiol. Renal Physiol. 282: F144-F150.
76. Oyekan, A. 2002. Nitric oxide inhibits renal cytochrome P450-dependent epoxygenases in the rat. Clin. Exp. Pharmacol. Physiol. 29: 990-995.
77. Serhan, C. N., and N. Chiang. 2008. En dogenous pro-resolving and anti-infl ammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol. 153 ( Suppl 1 ): S200-S215.